Largescale multicenter study of a serum metabolite biomarker panel for the diagnosis of breast cancer
Yanzhong Wang,
Rui An,
Haitao Yu,
Yuehong Dai,
Luping Lou,
Sheng Quan,
Rongchang Chen,
Yanjun Ding,
Hongcan Zhao,
Xuanlan Wu,
Zhen Liu,
Qinchuan Wang,
Yuzhen Gao,
Xinyou Xie,
Jun Zhang
Affiliations
Yanzhong Wang
Department of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, 3 East Qingchun Road, Hangzhou, Zhejiang, People’s Republic of China; Key Laboratory of Precision Medicine in Diagnosis and Monitoring Research of Zhejiang Province, 3 East Qingchun Road, Hangzhou, Zhejiang, People’s Republic of China
Rui An
Department of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, 3 East Qingchun Road, Hangzhou, Zhejiang, People’s Republic of China; Key Laboratory of Precision Medicine in Diagnosis and Monitoring Research of Zhejiang Province, 3 East Qingchun Road, Hangzhou, Zhejiang, People’s Republic of China
Haitao Yu
Department of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, 3 East Qingchun Road, Hangzhou, Zhejiang, People’s Republic of China; Key Laboratory of Precision Medicine in Diagnosis and Monitoring Research of Zhejiang Province, 3 East Qingchun Road, Hangzhou, Zhejiang, People’s Republic of China
Yuehong Dai
Department of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, 3 East Qingchun Road, Hangzhou, Zhejiang, People’s Republic of China
Luping Lou
Department of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, 3 East Qingchun Road, Hangzhou, Zhejiang, People’s Republic of China
Sheng Quan
Hangzhou Calibra Diagnostics Co., Ltd. (A Subsidiary of DIAN Diagnostics), 329 Jinpeng Street, Xihu Industrial Park, Hangzhou, Zhejiang, People’s Republic of China
Rongchang Chen
Hangzhou Calibra Diagnostics Co., Ltd. (A Subsidiary of DIAN Diagnostics), 329 Jinpeng Street, Xihu Industrial Park, Hangzhou, Zhejiang, People’s Republic of China
Yanjun Ding
Department of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, 3 East Qingchun Road, Hangzhou, Zhejiang, People’s Republic of China; Key Laboratory of Precision Medicine in Diagnosis and Monitoring Research of Zhejiang Province, 3 East Qingchun Road, Hangzhou, Zhejiang, People’s Republic of China
Hongcan Zhao
Department of Clinical Laboratory, Affiliated Hangzhou First People’s Hospital, Westlake University School of Medicine, 261 Huansha Road, Hangzhou, Zhejiang, People’s Republic of China
Xuanlan Wu
Department of Clinical Laboratory, Sir Run Run Shaw Hospital Xiasha Campus, Zhejiang University School of Medicine, 368 Xiasha Road, Hangzhou, Zhejiang, People’s Republic of China
Zhen Liu
Department of Clinical Laboratory, Ningbo Medical Centre Lihuili Hospital, Ningbo University, 1111 Jiangnan Street, Ningbo, Zhejiang, People’s Republic of China
Qinchuan Wang
Department of Surgical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, 3 East Qingchun Road, Hangzhou, Zhejiang, People’s Republic of China
Yuzhen Gao
Department of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, 3 East Qingchun Road, Hangzhou, Zhejiang, People’s Republic of China; Key Laboratory of Precision Medicine in Diagnosis and Monitoring Research of Zhejiang Province, 3 East Qingchun Road, Hangzhou, Zhejiang, People’s Republic of China
Xinyou Xie
Department of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, 3 East Qingchun Road, Hangzhou, Zhejiang, People’s Republic of China; Key Laboratory of Precision Medicine in Diagnosis and Monitoring Research of Zhejiang Province, 3 East Qingchun Road, Hangzhou, Zhejiang, People’s Republic of China
Jun Zhang
Department of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, 3 East Qingchun Road, Hangzhou, Zhejiang, People’s Republic of China; Key Laboratory of Precision Medicine in Diagnosis and Monitoring Research of Zhejiang Province, 3 East Qingchun Road, Hangzhou, Zhejiang, People’s Republic of China; Corresponding author
Summary: Breast cancer (BC) is currently the most prevalent malignancy worldwide, and finding effective non-invasive biomarkers for routine clinical detection of BC remains a significant challenge. Here, we performed non-targeted and targeted metabolomics analysis on the screening, training and validation cohorts of serum samples from 1,947 participants. A metabolite biomarker model including glutamate, erythronate, docosahexaenoate, propionylcarnitine, and patient’s age was established for detecting BC. This model demonstrated better diagnostic performance than carbohydrate antigen 15-3 (CA15-3) and carcinoembryonic antigen (CEA) alone in discriminating BC from healthy controls both in the training and validation cohorts [area under the curve (AUC), 0.954; sensitivity, 87.1% and specificity, 93.5% for the training cohort and 0.834, 68.3%, and 85.2%, respectively, for the validation cohort 1]. This study has established a noninvasive approach for the detection of BC, which shows potential as a suitable supplement to the clinical screening methods currently employed for BC.
